DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for obesity — screening already-approved drugs against its 45-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleObesity maps to a 45-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for obesity is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
alcohol dehydrogenase 1B (class I), beta polypeptide (ADH1B) — ADH1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet naddrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1U3U · 1.6 Å · ligand NICOTINAMIDE-ADENINE-DINUCLEOTIDE (NAD). Experimental structure, not a prediction.
What the evidence adds up to
In a 1998 study of 62 patients who underwent vertical banded gastroplasty for clinically severe obesity, 84% lost at least half of their excess weight within the first year. Of 218 weight-related conditions present before surgery, 60% were completely cured, 23% improved, and 17% remained unchanged over 12 to 48 months of follow-up. The authors concluded that surgical treatment significantly reduces obesity-associated disorders.
A 2009 retrospective analysis of 115 patients in a multidisciplinary clinic reported a mean weight loss of 6.6 kg and a waist circumference reduction of 6.7 cm after one year. Blood pressure and lipid profiles improved, but the proportion of patients taking metformin, lipid-lowering drugs, antihypertensives, or anti-obesity medications increased over the same period. The authors noted that weight loss occurred independently of diabetes status or use of anti-obesity drugs.
A 2020 prospective evaluation of a health-insurance-financed obesity programme in Germany followed 243 patients for an average of 72 weeks. Mean weight loss was 5 kg, or 4% of initial body weight. Haemoglobin A1c fell from 5.9% to 5.6% overall, and from 6.7% to 6.2% in diabetic patients. Low-density lipoprotein, total cholesterol, and quality of life also improved significantly.
A 2008 commentary on drug therapy for obesity noted that many drugs have had addictive or toxic properties requiring discontinuation. It stated that obesity is a chronic disease that cannot be cured but can be treated, and that pharmacotherapy is reserved for those who have failed behavioural weight loss attempts or as an adjunct to them. The commentary emphasised that treatment will generally be lifelong. What remains missing across these approaches is long-term cost-effectiveness data from prospective trials, standardised patient stratification for non-surgical programmes, and sustained funding for comparative studies that directly measure drug, behavioural, and surgical outcomes against each other.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Southern Medical Journal · 1998 · 42 citations
Disorders Associated With Clinically Severe Obesity: Significant Improvement After Surgical Weight Reduction
AbstractBACKGROUND: Surgical treatment for patients with clinically severe obesity mainly aims to reduce morbidity. METHODS: Sixty-two patients were examined for disorders associated with morbid obesity before and after surgical weight reduction by vertical banded gastroplasty. All patients were followed-up for 12 to 48 months. RESULTS: At the end of the first postoperative year, 84% of the patients had lost at least 50% of their excess weight. Of the 218 weight-related pathologic conditions existing before the operation, 131 (60%) were completely cured, 50 (23%) showed significant improvement, and only 37 (17%) remained unchanged. The same percentages were obtained for patients followed tip for 24, 36, and 48 postoperative months. CONCLUSIONS: Surgical treatment of clinically severe obesity has a significant effect on the health of the patients by eliminating the associated disorders.
Metabolic Syndrome and Related Disorders · 2009 · 13 citations
Effectiveness of a Multidisciplinary Program for Management of Obesity: The Unité d’Enseignement, de Traitement et de Recherche sur l’Obésité (UETRO) Database Study
AbstractBACKGROUND: Obesity is a worldwide health problem assuming epidemic proportions. Development of effective clinical interventions is needed to lower the impact of associated morbidity and mortality, without forgetting related costs. We have established an interdisciplinary clinic for obesity management, Unité d'Enseignement, de Traitement et de Recherche sur l'Obésité (UETRO), which consists of individual consultations combined with group sessions. We report here the effectiveness of this program for weight reduction over the first year of follow up. METHODS: We performed retrospective analysis of standardized patient records of the first 115 consecutive subjects referred to UETRO with available follow up for 1 year. RESULTS: Mean age, body mass index (BMI), and waist circumference (WC) of our cohort were 46 +/- 13 years, 44.7 +/- 0.9 kg/m(2), and 120.5 +/- 1.9 cm, respectively. Hypertension and diabetes were present in 46% and 23% of our patients. Weight and WC loss were gradual over 1 year and were significantly reduced by 6.6 +/- 0.8 kg and 6.7 +/- 0.7 cm, respectively (P < 0.001), without attainment of a plateau. Blood pressure and lipid profile significantly improved after 1 year of follow up. However, the proportion of patients taking metformin, lipid-lowering, antihypertensive, or antiobesity drugs increased significantly over follow up, reflecting intensification of treatment of co-morbidities and weight management. Significant weight and WC loss occurred independently of diabetes status and use of antiobesity medications. CONCLUSIONS: This program appears to be as effective for treating obesity as more intensive treatment programs. Future prospective studies are needed to evaluate the benefits and costs of this therapeutic approach.
[Closing the gap in conservative obesity therapy: a fully health insurance-financed obesity program - Prospective analysis of clinical real world data].
AbstractBACKGROUND: ). Here we evaluate the effectiveness of the first part of the program which was on average 72 weeks long. METHODS: ). The whole first treatment part was completed by 243 persons. The analysis design was a prospective evaluation of clinical real world data. RESULTS: . On average, patients lost 5 kg (95 % confidence interval, KI 3.8 to 6.2 kg) or 4 % (KI 3.1 to 4.9 %) of their initial body weight. The hemoglobin A1c value decreased from 5.9 % to 5.6 % in all patients and from 6.7 % to 6.2 % in diabetic patients. Further metabolic (e. g., low density lipoprotein and total cholesterol) and psychological (e. g., quality of life) parameters improved significantly as well. CONCLUSIONS: " contributes to improving long-term treatment of obesity in Germany.
AbstractDrug therapy for obesity has had a difficult past history. A number of drugs have had addictive or toxic properties that have required discontinuation. Pharmacotherapy for obesity has an important role in those persons who have failed behavioral weight loss attempts or as an adjunct to those attempts. The interest in pharmacotherapy for obesity is an outgrowth of the now general recognition that it is a chronic disease that cannot be cured, but can be treated. Treatment, however, will generally be a life-long affair. The focus on drug therapy is due to the frequent failure of non-pharmacological weight loss programs.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
